Results 61 to 70 of about 44,337 (260)

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial)

Canadian Respiratory Journal, 2009
AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.
J Mark FitzGerald, Sylvain Foucart, Stephen Coyle, John Sampalis, Denis Haine, Eliofotisti Psaradellis, R Andrew McIvor   +6 more
doaj   +1 more source

Extrafine inhaled corticosteroid therapy in the control of asthma

, 2013
István Ivancsó, Renáta Böcskei, Veronika Müller, Lilla Tamási Department of Pulmonology, Semmelweis University, Budapest, Hungary Abstract: Small airways disease plays an important role in the pathogenesis of asthma,
Ivancsó I, Tamási L, Müller V, Böcskei R   +3 more
core  

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial

Trials, 2018
Background Patients with difficult-to-control asthma consume 50–60% of healthcare costs attributed to asthma and cost approximately five-times more than patients with mild stable disease.
Catherine E. Hanratty, John G. Matthews, Joseph R. Arron, David F. Choy, Ian D. Pavord, P. Bradding, Christopher E. Brightling, Rekha Chaudhuri, Douglas C. Cowan, Ratko Djukanovic, Nicola Gallagher, Stephen J. Fowler, Tim C. Hardman, Tim Harrison, Cécile T. Holweg, Peter H. Howarth, James Lordan, Adel H. Mansur, Andrew Menzies-Gow, Sofia Mosesova, Robert M. Niven, Douglas S. Robinson, Dominick E. Shaw, Samantha Walker, Ashley Woodcock, Liam G. Heaney, on behalf of the RASP-UK (Refractory Asthma Stratification Programme) Consortium   +26 more
doaj   +1 more source

Respiratory medication use in Australia 2003–2013: treatment of asthma and COPD [PDF]

, 2015
This report describes patterns of dispensing of respiratory medications in Australia through detailed analyses of Pharmaceutical Benefits Scheme data, as well as other sources, to draw inferences about respiratory medication use among patients with ...
Leanne Poulos, Patricia Correll, H. K. Reddel, Rosario Ampon, Guy Marks   +4 more
core  

The Airway Epithelial Barrier in Childhood Asthma: A Central Player in Glucocorticoid Therapy, Resistance, and Severe Asthma

Pediatric Discovery, EarlyView.
ABSTRACT Childhood asthma remains a global public health challenge with suboptimal control, despite the availability of inhaled corticosteroids (ICS) as first‐line therapy. Glucocorticoids suppress inflammation and protect the airway epithelial barrier (AEB) via genomic and nongenomic pathways.
Tangqiaochu Gan, Zhou Fu, Chao Niu
wiley   +1 more source

Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide.

, 2012
BACKGROUND AND PURPOSEInhaled corticosteroids (ICS) are the cornerstone of asthma pharmacotherapy and, acting via the glucocorticoid receptor (GR), reduce inflammatory gene expression.
M. M. Kelly (14856258), R. Newton (7152743), Neil Holden (17160016), C. Gwozd (17190388), B. Zuraw (17190382), E. M. King (17190391), R. Leigh (3501593), P. M. O'Byrne (17190397), C. F. Rider (17190385), J. Eddleston (17190394)   +9 more
core   +1 more source

Effects of Hydrofluoroalkane and Dry Powder-Formulated Corticosteroids on Sputum Inflammatory Markers in Asthmatic Patients

Canadian Respiratory Journal, 2006
BACKGROUND: Inhaled corticosteroids are powerful drugs that can suppress airway inflammation in asthmatic patients. Deposition of most of the inhaled corticosteroid occurs mainly in the central airways.
Hans-Peter Hauber, Rame Taha, Celine Bergeron, Vladimir Migounov, Qutayba Hamid, Ron Olivenstein   +5 more
doaj   +1 more source

The use of inhaled corticosteroids in the treatment, of bronchial asthma with particular reference to beclomethasome dipropionate.

, 1975
MDThe Problem : Corticosteroids may be necessary to control the symptoms of many patients with chronic bronchial asthma, their use, however, is frequently complicated by side effects, which are unpleasant for the patient and often worrying for the ...
Harris, D.M.
core